Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11129742 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28709745 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11129711 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28712104 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8368430 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28712221 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2253804 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL206091 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11127456 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28314266 | 1.00 | MEN1 (0.69) | MEN1KMT2ATP53MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040500-A | Soluble unsaturated double quaternary ammonium bisphosphonate | 江苏海洋大学 | 2025-05-27 | — | — | CN | claimed |
| CN-120040501-A | Double phosphonic acid double salt containing acryloyloxy and quaternary ammonium cations | 江苏海洋大学 | 2025-05-27 | — | — | CN | claimed |
| CN-108101276-A | Industrial wastewater treatment device | 南京悠谷新材料科技有限公司 | 2018-06-01 | — | — | CN | claimed |
| EP-2181596-B1 | METHOD OF INHIBITING THE GROWTH OF MICROORGANISM IN AQUEOUS SYSTEMS USING A COMPOSITION COMPRISING LYSOZYME | BUCKMAN LABOR INC (US) | 2015-07-08 | — | — | EP | claimed |
| EP-1585502-B9 | FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN | ELAN PHARMA INT LTD (IE) | 2012-05-09 | — | — | EP | claimed |
| EP-1585502-B1 | FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN | ELAN PHARMA INT LTD (IE) | 2011-06-29 | — | — | EP | claimed |
| EP-2152274-A1 | NASAL ADMINISTRATION OF BENZODIAZEPINES | Questor Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008137960-A1 | NASAL ADMINISTRATION OF BENZODIAZEPINES | QUESTOR PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| EP-1981988-A2 | ANTISEPTIC COMPOSITIONS AND METHODS OF USING SAME | Do-Coop Technologies Ltd (IL) | 2008-10-22 | — | — | EP | claimed |
| WO-2007100514-A1 | HALOPEROXIDASE TREATMENT TO CONTROL ALGAE | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 2007-09-07 | — | — | WO | claimed |
| US-20070197388-A1 | Haloperoxidase treatment to control algae | BUCKMAN LABORATORIES INTERNATIONAL, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007077562-A2 | ANTISEPTIC COMPOSITIONS AND METHODS OF USING SAME | DO-COOP TECHNOLOGIES LTD. (IL) | 2007-07-12 | — | — | WO | claimed |
| US-20020168423-A1 | High strength liquid antiseptic | WURZBURGER STEPHEN RAY (US) | 2002-11-14 | — | — | US | claimed |
| US-4839168-A | PLANT EXTRACT AND POLYPEPTIDE COMPOUND | KAO CORPORATION (JP) | 1989-06-13 | — | — | US | claimed |
| US-4764527-A | Hydroxypyrazole derivatives, composition containing them and their use against microorganisms | BASF AKTIENGESELLSCHAFT (DE) | 1988-08-16 | — | — | US | claimed |
| CN-120040501-A | Double phosphonic acid double salt containing acryloyloxy and quaternary ammonium cations | 江苏海洋大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-120040500-A | Soluble unsaturated double quaternary ammonium bisphosphonate | 江苏海洋大学 | 2025-05-27 | — | — | CN | disclosed |
| US-4124493-A | Catalytic oxidation of mercaptan in petroleum distillate including alkaline reagent and substituted ammonium halide | UOP INC. (US) | 1978-11-07 | — | — | US | disclosed |
| US-3954712-A | Hot-curable mixtures based on epoxide resin | CIBA-GEIGY CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
| US-3950371-A | EVAPORATION OF AQUEOUS ELECTROLYTE | HENKEL & CIE G.M.B.H. (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168423-A1 | High strength liquid antiseptic | CUTA, LIPA, POLR1C | ACHE 1352/4885MEN1 4619/4885KMT2A 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.